VSTM Key Stats
- Verastem's CEO Discusses Q4 2013 Results - Earnings Call Transcript Seeking Alpha 03/06 14:26 ET
- Streetinsider.com's Hot Lunchtime Reads 03/06: (AAPL) (HOLX) (VSTM) (BJRI) Street Insider 03/06 12:13 ET
- Roth Keeps Verastem (VSTM) at Buy; Sees Positioned for 'Potentially Transformative Year' Street Insider 03/06 11:33 ET
- VERASTEM, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits Yahoo 03/06 09:35 ET
- Verastem Reports Year-End 2013 Financial Results noodls 03/06 08:47 ET
- Verastem Inc Earnings Call scheduled for 8:00 am ET today Yahoo 03/06 08:00 ET
- Q4 2013 Verastem Inc Earnings Release - Before Market Open Yahoo 03/06 07:07 ET
- Verastem Reports Data from Phase 1 Study of VS-6063 (defactinib) in Japanese Patients Business Wire 03/05 17:00 ET
- Verastem to Present at Upcoming Investor Conferences noodls 03/04 08:15 ET
- Verastem Supports Worldwide Rare Disease Day on February 28, 2014 noodls 02/28 08:28 ET
VSTM Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Verastem is up 56.71% over the last year vs S&P 500 Total Return up 24.21%, Poniard Pharmaceuticals up 34.04%, and Actelion up 98.29%.
Balance Sheet View Statement
Pro Ratings for VSTM
Pro Strategies Featuring VSTM
Did Verastem make it into our Pro Portfolio Strategies?
Start your YCharts Pro membership now to find out.
- Sector: Healthcare
- Industry: Biotechnology
- Headquarters Country: United States
- Headquarters State/Province: Massachusetts
- Incorporation Country: United States
- Incorporation State/Province: Delaware
Verastem Inc is a biopharmaceutical company focused on discovering and developing proprietary small molecule drugs targeting cancer stem cells along with proprietary companion diagnostics.